Arcus Biosciences (NYSE:RCUS) Stock Falls 4.9% - Time to Sell?

Key Points

• Arcus shares fell 4.9% to about $22.58 in midday trading, with volume down 79% from the average.
• Analysts remain broadly optimistic after encouraging ARC-20 data for casdatifan in kidney cancer; Wedbush upgraded the stock to “outperform” with a $49 target, while the consensus rating is “Moderate Buy” with a $39.18 target.
• Risks remain significant: casdatifan is still in clinical development, the stock carries a demanding valuation, and investors expect another quarterly loss despite the company beating its latest EPS and revenue estimates.

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report)'s share price fell 4.9% during mid-day trading on Wednesday. The company traded as low as $22.94 and last traded at $22.5750. 278,770 shares traded hands during trading, a decline of 79% from the average daily volume of 1,322,284 shares. The stock had previously closed at $23.75.

Key Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Wedbush raised its price target to $49 from $43 and upgraded its view to “outperform,” implying substantial upside from recent trading levels. Truist Financial also increased its target to $41 from $40 and assigned a “buy” rating.
• Positive Sentiment: New ARC-20 data showed casdatifan activity across first-line, second-line and later-line clear cell renal cell carcinoma. The drug’s combinations delivered competitive or superior progression-free survival and response rates versus historical benchmarks, with manageable safety reported. This supports the potential for casdatifan to become a foundational treatment across multiple lines of therapy. ARC-20 casdatifan data
• Positive Sentiment: Analysts reacted favorably to the kidney-cancer results, helping Arcus shares increase during the prior session after an initially negative reaction to the data. Analysts cheer ARC-20 data
• Neutral Sentiment: The data are encouraging but remain clinical-stage evidence; further trials, regulatory review and commercial execution will be required before the opportunity is validated.
• Negative Sentiment: Arcus trades at a demanding valuation—approximately 22.5 times trailing sales and 37.9 times forward sales—leaving the stock vulnerable to setbacks in casdatifan’s development. Casdatifan valuation analysis
• Negative Sentiment: Investors are also bracing for potentially negative third-quarter earnings, with expectations pointing to another loss and no clear indication of an earnings beat. Arcus earnings outlook

Wall Street Analyst Weigh In

A number of equities research analysts have commented on RCUS shares. Morgan Stanley set a $23.00 price objective on Arcus Biosciences in a research note on Monday, August 10th. Cantor Fitzgerald restated an "overweight" rating on shares of Arcus Biosciences in a research note on Friday, September 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Arcus Biosciences in a report on Thursday, October 15th. Wells Fargo & Company raised their price objective on shares of Arcus Biosciences from $23.00 to $26.00 and gave the company an "equal weight" rating in a research note on Thursday, August 6th. Finally, Wedbush raised their price objective on shares of Arcus Biosciences from $43.00 to $49.00 and gave the company an "outperform" rating in a research note on Wednesday. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $39.18.

Arcus Biosciences Price Performance

The business's fifty day moving average is $26.73 and its 200-day moving average is $26.25. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82. The firm has a market cap of $2.65 billion, a PE ratio of -5.39 and a beta of 0.94.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%. The business had revenue of $41.00 million for the quarter, compared to the consensus estimate of $21.98 million. The company's revenue was down 74.4% on a year-over-year basis. On average, research analysts predict that Arcus Biosciences, Inc. will post -3.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Alexander Azoy sold 2,827 shares of the business's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the sale, the chief accounting officer directly owned 39,581 shares in the company, valued at approximately $1,187,430. The trade was a 6.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.60% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC purchased a new position in Arcus Biosciences during the second quarter valued at $30,000. KBC Group NV purchased a new stake in shares of Arcus Biosciences in the 1st quarter worth about $50,000. Royal Bank of Canada increased its stake in shares of Arcus Biosciences by 14.6% in the 1st quarter. Royal Bank of Canada now owns 4,758 shares of the company's stock worth $102,000 after acquiring an additional 607 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Arcus Biosciences by 10.0% in the 2nd quarter. GAMMA Investing LLC now owns 3,966 shares of the company's stock worth $122,000 after acquiring an additional 359 shares in the last quarter. Finally, Nykredit A S bought a new position in shares of Arcus Biosciences in the 2nd quarter worth about $134,000. Institutional investors own 92.89% of the company's stock.

About Arcus Biosciences

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus's oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.